Reimbursement Review Reports


( Last Updated : May 25, 2022)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort ascending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Zytram XL Tramadol hydrochloride Pain, acute Withdrawn
Zytram XL Tramadol hydrochloride Pain, acute Do not list Complete
Zolinza vorinostat Cutaneous T-cell lymphoma CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Zolgensma onasemnogene abeparvovec Spinal muscular atrophy (SMA), pediatrics Reimburse with clinical criteria and/or conditions Complete
Zinbryta Daclizumab beta Multiple Sclerosis, relapsing-remitting Reimburse with clinical criteria and/or conditions Complete
Zepzelca lurbinectedin metastatic small cell lung cancer (SCLC) Active
Zeposia ozanimod Multiple Sclerosis, relapsing - remitting Do not reimburse Complete
Zeposia ozanimod Ulcerative colitis Active
Zepatier Elbasvir/grazoprevir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete
Zenhale (inhalation aerosol) Mometasone furoate and formoterol Asthma Do not list Complete